Latest news with #Curaleaf
Yahoo
21 hours ago
- Business
- Yahoo
E-Commerce Surge Boosting Expansion, SoRSE Emulsion Technology Enhancing Cannabis Beverage Experience
The Cannabis-Infused Products Market is set for exponential growth, reaching $78.51 billion by 2029 at a CAGR of 23.4%. Key factors include increasing legalization, consumer demand for wellness solutions, and innovative technologies like SōRSE emulsion. Major players include Curaleaf, Aurora Cannabis, and Tilray. North America leads the market. Cannabis-Infused Products Market Dublin, July 29, 2025 (GLOBE NEWSWIRE) -- The "Cannabis-Infused Products Market Report 2025" report has been added to cannabis-infused products market size has grown exponentially in recent years. It will grow from $27.37 billion in 2024 to $33.85 billion in 2025 at a compound annual growth rate (CAGR) of 23.7%. The cannabis-infused products market size is expected to see exponential growth in the next few years. It will grow to $78.51 billion in 2029 at a compound annual growth rate (CAGR) of 23.4%. This Cannabis-Infused Products Market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market. The growth during the historic period can be attributed to the increasing legalization of cannabis, growing consumer awareness, a rise in medical cannabis applications, innovations in product formulations, and the expansion of distribution growth during the forecast period can be attributed to ongoing legalization trends, rising demand for wellness products, increasing investment in research and development, growing acceptance of CBD products, and the expansion of e-commerce platforms. Key trends in the forecast period include the use of nanotechnology for better absorption, advanced extraction techniques, the development of cannabis-based beverages, AI-driven product innovation, and the adoption of blockchain for supply chain growth of e-commerce is expected to drive the expansion of the cannabis-infused products market in the future. E-commerce refers to the buying and selling of goods and services over the internet, facilitating transactions through online platforms and digital payment systems. This sector is growing due to increased internet penetration, shifting consumer preferences for online shopping, and advancements in digital payment solutions, making online shopping more convenient and accessible. Cannabis-infused products are benefiting from e-commerce by meeting the rising demand for wellness and alternative health solutions. They offer a variety of products that can be easily accessed, purchased, and delivered through online platforms. For example, in May 2024, the United States Census Bureau reported that U.S. retail e-commerce sales reached $289.2 billion in the first quarter of 2024, marking a 2.1% increase compared to the fourth quarter of 2023. This growth in e-commerce is contributing to the expansion of the cannabis-infused products in the cannabis-infused products market are focusing on innovative technologies, such as SoRSE emulsion technology, to improve the bioavailability and taste of cannabis-infused beverages and edibles, enhancing the overall consumer experience. SoRSE emulsion technology is a patented water-soluble emulsion platform designed to improve the bioavailability, stability, and sensory experience of cannabis and other functional ingredients in consumable products. For instance, in January 2024, Aurora Cannabis Inc., a Canada-based cannabis company, launched a new line of cannabis-infused beverages, including Neon Rush, Strawberry Pineapple Tropical Fizz, and Pineapple Coconut Fizz. These beverages combine precise dosage control with the convenience of a drink, allowing consumers to enjoy consistent effects in an easy-to-consume form. They utilize SoRSE emulsion technology, ensuring better bioavailability of cannabinoids, which leads to faster onset times and more predictable effects. The beverages also feature a smooth taste that masks the natural bitterness of cannabis, appealing to both seasoned users and December 2024, Organigram Holdings Inc., a Canada-based company specializing in the production of medical cannabis products, acquired Motif Labs Ltd. for an undisclosed amount. This acquisition aims to strengthen Organigram's market position, broaden its product range, and enhance its capabilities in the cannabis-infused products segment, solidifying its leadership in the Canadian cannabis industry. Motif Labs Ltd. is a Canadian company known for producing high-quality cannabis extracts and innovative America was the largest region in the cannabis-infused products market in 2024. The regions covered in cannabis-infused products report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cannabis-infused products market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Attributes: Report Attribute Details No. of Pages 175 Forecast Period 2025 - 2029 Estimated Market Value (USD) in 2025 $33.85 Billion Forecasted Market Value (USD) by 2029 $78.51 Billion Compound Annual Growth Rate 23.4% Regions Covered Global Key Topics Covered: 1. Executive Summary2. Cannabis-Infused Products Market Characteristics3. Cannabis-Infused Products Market Trends and Strategies4. Cannabis-Infused Products Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market5. Global Cannabis-Infused Products Growth Analysis and Strategic Analysis Framework5.1. Global Cannabis-Infused Products PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)5.2. Analysis of End Use Industries5.3. Global Cannabis-Infused Products Market Growth Rate Analysis5.4. Global Cannabis-Infused Products Historic Market Size and Growth, 2019-2024, Value ($ Billion)5.5. Global Cannabis-Infused Products Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion)5.6. Global Cannabis-Infused Products Total Addressable Market (TAM)6. Cannabis-Infused Products Market Segmentation6.1. Global Cannabis-Infused Products Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Skincare Cosmetics Haircare Intimate Lubricants Gummies Pills Infused Beverages 6.2. Global Cannabis-Infused Products Market, Segmentation by Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Hemp Marijuana 6.3. Global Cannabis-Infused Products Market, Segmentation by Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion B2B B2C 6.4. Global Cannabis-Infused Products Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Medical Personal Use Pharmaceuticals Wellness 6.5. Global Cannabis-Infused Products Market, Sub-Segmentation of Skincare, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion CBD-Infused Lotions Cannabis-Infused Face Serums Hemp-Infused Moisturizers 6.6. Global Cannabis-Infused Products Market, Sub-Segmentation of Cosmetics, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Cannabis-Infused Foundations CBD-Infused Lip Balms Hemp-Infused Mascaras 6.7. Global Cannabis-Infused Products Market, Sub-Segmentation of Haircare, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion CBD-Infused Shampoos Cannabis-Infused Conditioners Hemp-Infused Hair Oils 6.8. Global Cannabis-Infused Products Market, Sub-Segmentation of Intimate Lubricants, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion CBD-Infused Lubricants THC-Infused Lubricants Hybrid Cannabis Lubricants 6.9. Global Cannabis-Infused Products Market, Sub-Segmentation of Gummies, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion CBD Gummies THC Gummies Full-Spectrum Cannabis Gummies 7. Cannabis-Infused Products Market Regional and Country Analysis7.1. Global Cannabis-Infused Products Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion7.2. Global Cannabis-Infused Products Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Cannabis-Infused Products Market Competitive Landscape and Company Profiles Curaleaf Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis Trulieve Cannabis Corp. Overview, Products and Services, Strategy and Financial Analysis Green Thumb Industries Inc. Overview, Products and Services, Strategy and Financial Analysis Cresco Labs Inc. Overview, Products and Services, Strategy and Financial Analysis Tilray Inc. Overview, Products and Services, Strategy and Financial Analysis Cannabis-Infused Products Market Other Major and Innovative Companies Columbia Care Inc. Canopy Growth Corporation MedMen Enterprises Inc. Aurora Cannabis Inc. Eaze Inc. Pax Labs Flow Kana Inc. Kiva Brands Inc. Charlotte's Web Holdings Inc. Vireo Health International Inc. The Green Organic Dutchman Holdings Ltd. Indus Holdings Inc. THC Design Inc. Herbivore Botanicals Baked Bros LLC For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Cannabis-Infused Products Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Why Curaleaf Stock Surged 13% Higher Today
Key Points A letter sent by a clutch of attorneys general to congressional leaders made a case for banking reform for the marijuana industry. Lack of access to basic financial services has been quite a hindrance for the business. 10 stocks we like better than Curaleaf › A new political push for marijuana law reform had an intoxicating effect on Curaleaf (OTC: CURLF) stock as the trading week came to an end. On Friday, the multi-state operator (MSO) was quite the buzzy title on the exchange, with investors boosting its share price by 13% on the day. That compared quite favorably to the minor (0.4%) gain of the S&P 500 (SNPINDEX: ^GSPC) at market close. Banking on change Late on Thursday, a group of 32 attorneys general from U.S. states and territories sent a letter to congressional leaders imploring them to pass a marijuana banking bill. The Secure and Fair Enforcement Regulation (SAFER) Banking Act would allow cannabis businesses to access basic financial services; as the drug is illegal at the federal (if not necessarily the state) level, they are currently barred from these. Many are consequently forced to operate on a cash-only basis, which increases the risks of crime. In the letter, the attorneys general wrote, "As more states continue to consider and implement legalization efforts, the lack of access to America's financial system by cannabis businesses -- which is a direct result of federal banking law -- presents a considerable safety issue for the public." Democrats and Republicans alike Reflecting the broad support marijuana legalization enjoys among the general American public, the 32 attorneys general -- from locales such as Maryland; Washington, D.C.; and Georgia -- are a bipartisan group. While it remains to be seen what, if any, effect their letter has on the rather slow-moving Congressional pot reform efforts, it's good for the weed industry that there continues to be pressure for change. Should you buy stock in Curaleaf right now? Before you buy stock in Curaleaf, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Curaleaf wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,774!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,942!* Now, it's worth noting Stock Advisor's total average return is 1,040% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Curaleaf Stock Surged 13% Higher Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
4 days ago
- Business
- Globe and Mail
Why Curaleaf Stock Surged 13% Higher Today
Key Points A letter sent by a clutch of attorneys general to congressional leaders made a case for banking reform for the marijuana industry. Lack of access to basic financial services has been quite a hindrance for the business. 10 stocks we like better than Curaleaf › A new political push for marijuana law reform had an intoxicating effect on Curaleaf (OTC: CURLF) stock as the trading week came to an end. On Friday, the multi-state operator (MSO) was quite the buzzy title on the exchange, with investors boosting its share price by 13% on the day. That compared quite favorably to the minor (0.4%) gain of the S&P 500 (SNPINDEX: ^GSPC) at market close. Banking on change Late on Thursday, a group of 32 attorneys general from U.S. states and territories sent a letter to congressional leaders imploring them to pass a marijuana banking bill. The Secure and Fair Enforcement Regulation (SAFER) Banking Act would allow cannabis businesses to access basic financial services; as the drug is illegal at the federal (if not necessarily the state) level, they are currently barred from these. Many are consequently forced to operate on a cash-only basis, which increases the risks of crime. In the letter, the attorneys general wrote, "As more states continue to consider and implement legalization efforts, the lack of access to America's financial system by cannabis businesses -- which is a direct result of federal banking law -- presents a considerable safety issue for the public." Democrats and Republicans alike Reflecting the broad support marijuana legalization enjoys among the general American public, the 32 attorneys general -- from locales such as Maryland; Washington, D.C.; and Georgia -- are a bipartisan group. While it remains to be seen what, if any, effect their letter has on the rather slow-moving Congressional pot reform efforts, it's good for the weed industry that there continues to be pressure for change. Should you invest $1,000 in Curaleaf right now? Before you buy stock in Curaleaf, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Curaleaf wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,774!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,942!* Now, it's worth noting Stock Advisor's total average return is 1,040% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025
Reuters
16-07-2025
- Business
- Reuters
Breakingviews - Big Cannabis puts its growth hopes in dud buds
LONDON, July 14 (Reuters Breakingviews) - The weed sector is not as high as it used to be. A slow revenue grind and relentless regulatory hits have left Big Cannabis facing a chronic funk. Budding opportunities, like the flowering German market, may see some North American groups cough up for a deal to plant a foreign seed. Yet a mellow mood, and puffed-out stock valuations, are probably baked-in for the foreseeable future. Back in 2021, the much-hyped movement seemed to be sparking into life. Nearly 18 million Americans admitted to using the herb on a daily basis, overtaking the near-15 million daily drinkers, according to a survey published in the journal Addiction, opens new tab. New York, Virginia, Connecticut and New Mexico legalised recreational cannabis, as Alabama did for medical use. Hopes abounded that then-President Joe Biden might breathe life into federal reform, making it easier for companies to access financial services and manage inventory across state lines. The ambient buzz saw the combined value of Curaleaf ( opens new tab, Green Thumb Industries ( opens new tab, Tilray Brands (TLRY.O), opens new tab and Trulieve Cannabis ( opens new tab peak at $37 billion in February 2021. The same quartet, whose operations span everything from growing to packaging and selling weed and related products, at the time had an eye-watering average valuation multiple of 15 times forward sales, according to Breakingviews calculations based on LSEG Datastream figures. The dreams behind those numbers, however, have gone up in smoke. That much was evident at an industry gathering at the Barbican Centre in London last month, where top investors, CEOs and bankers bluntly hashed out the sector's biggest risks and opportunities. Attendees of Cannabis Europa, opens new tab, some bleary-eyed after wading through plumes of smoke, heard that right-leaning governments worldwide are blocking the opening up of new recreational markets. Sticky corporate debt burdens and low valuation multiples, meanwhile, have made expansion tricky. It's reflected in the stock market. Curaleaf, Green Thumb, Tilray and Trulieve are now collectively worth just $4 billion, LSEG data shows, with an average forward revenue multiple of just over 1. On aggregate, they'll make a loss this year and next, based on analysts' forecasts gathered by Visible Alpha. One long-term problem is that legalisation in the United States and Canada sparked a rush of supply, leading to a glut of marijuana and therefore much lower prices amid cutthroat competition. In New York, the number of registered dispensaries has exploded since legalisation in 2021 to 300 now, according to the Office of Cannabis Management. Average U.S. retail prices have declined by 32% over the same period, according to Cannabis Benchmarks, opens new tab. Companies are also facing the stark reality of a total addressable market that looks stagnant at best. As U.S. state laws criminalising the herb fell like dominoes, investors once thought other countries would eventually succumb too. That now looks like a pipe dream. Not a single U.S. state has legalised recreational cannabis this year or in 2024. President Donald Trump's government seems unlikely to do much. The Drug Enforcement Administration last year indicated that it might downgrade weed from the schedule one category under the Controlled Substances Act to schedule three, which could ease some federal restrictions and make more expenses tax-deductible. The process now seems stalled, however. In other markets, progress is being stubbed out. Last month, Thailand moved to ban recreational use amid concerns about addiction in younger users, having taken the drug off its narcotics list only three years earlier. Amid the haze, boosters are finding solace in an unlikely place. Germany last year decriminalised cannabis possession and small-scale production, while stopping short of allowing wholesale cultivation. Bankers and investors at the London conference giddily talked up the prospects of inbound Teutonic M&A, as companies in the U.S. and Canada look to take advantage of potential growth in Europe's biggest economy. Privately owned Demecan or Cannamedical could be prime targets. The legal German cannabis market could grow by 14% each year until 2030, according to a report from Research and Markets, opens new tab. But it's starting from a low base. Last year, the market was worth just $37 million. And there are other obstacles. Planned licences for pot shops and pharmacies, for example, have failed to materialise amid concerns from European leaders about a surge in illegal exports. It's all a far cry from the multibillion-dollar global dreams of a few years ago. But there's not much else to get excited about. Amid a drought of optimism, even the most unpromising of buds can seem like salvation. Follow Aimee Donnellan on LinkedIn, opens new tab.
Yahoo
08-07-2025
- Business
- Yahoo
Why Curaleaf Stock Is Smoking Hot Today
Curaleaf is buying out its minority partner in Europe. The former strategic investor in Curaleaf's European subsidiary is remaining invested in Curaleaf itself. Curaleaf generates substantial free cash flow and is growing nicely. 10 stocks we like better than Curaleaf › Curaleaf Holdings (OTC: CURLF), one of only a handful of publicly traded cannabis stocks that are headquartered in the U.S., jumped 4.8% through 11:30 a.m. ET Tuesday after announcing it has consolidated its stake in its European holding company, Curaleaf International Holdings Limited (CIHL). Curaleaf now owns 100% of the subsidiary. Since its initial foray into Europe in 2021, Curaleaf advises, an unnamed "single strategic institutional investor" has owned part of the equity in CIHL. Now Curaleaf owns it all, and takes all the risk that the business may perform poorly -- and will reap all the rewards if CIHL performs well. Curaleaf seems to think the latter option is more likely, as does its former institutional investor -- which has "elected to receive the purchase entirely in Curaleaf Subordinate Voting Shares." This means the investor eschewed the safety of getting paid in cash, and instead is keeping its cart firmly hitched to the horse that is the Curaleaf parent company. Or as Curaleaf put it: "The request of the strategic investor to settle the transaction for Company shares underscores the investor's long-term support and confidence in the future of Curaleaf." Practically speaking, it's as if the strategic investor took payment from Curaleaf for its stake in the subsidiary, and then immediately used that payment to buy shares in Curaleaf itself. But is Curaleaf stock really a good buy? I think it is. Curaleaf is the only marijuana stock I know of that generates positive free cash flow, nearly $63 million over the last year. That gives the stock a price-to-free cash flow ratio of almost exactly 10. So long as Curaleaf can maintain even a low-double-digit growth rate going forward, that should be cheap enough to buy. Before you buy stock in Curaleaf, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Curaleaf wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $695,481!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $969,935!* Now, it's worth noting Stock Advisor's total average return is 1,053% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Curaleaf Stock Is Smoking Hot Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
